Aclaris Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Aclaris Therapeutics has a total shareholder equity of $157.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $197.4M and $40.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$119.11m |
Equity | US$157.18m |
Total liabilities | US$40.23m |
Total assets | US$197.41m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0H8T's short term assets ($128.9M) exceed its short term liabilities ($31.0M).
Long Term Liabilities: 0H8T's short term assets ($128.9M) exceed its long term liabilities ($9.3M).
Debt to Equity History and Analysis
Debt Level: 0H8T is debt free.
Reducing Debt: 0H8T has no debt compared to 5 years ago when its debt to equity ratio was 13.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0H8T has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0H8T has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 4.2% each year.